BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
52 hedge funds and large institutions have $16.9M invested in BRAINSTORM CELL THERAPUTC in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 24 reducing their positions, and 10 closing their positions.
6% more call options, than puts
Call options by funds: $3.84M | Put options by funds: $3.62M
0.09% less ownership
Funds ownership: 1.03% → 0.94% (-0.09%)
9% less funds holding
Funds holding: 57 → 52 (-5)
21% less capital invested
Capital invested by funds: $21.4M → $16.9M (-$4.46M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
67% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$819K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$392K |
| 3 |
PVI
Pura Vida Investments
New York
|
+$375K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$137K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$68.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$886K |
| 2 |
Millennium Management
New York
|
-$776K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$363K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$331K |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$284K |
BCLI Hedge Fund Activity: Q3 2021 in Review
52 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2021, worth a combined $16.9M — down 21% from $21.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of BCLI and 5 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 8 added.
The largest buyer was Sabby Management, adding an estimated $819K. The largest seller was JP Morgan Chase, cutting an estimated $886K.
- 52 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2021, down from 57 in Q2 2021.
- Funds reported $16.9M of BRAINSTORM CELL THERAPUTC stock for Q3 2021, down 21% quarter-over-quarter.
- 5 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2021 and 10 closed out, a net change of -5 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2021 was Sabby Management, an estimated $819K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2021 was JP Morgan Chase, an estimated $886K sold.
Based on aggregated 13F filings for Q3 2021.